Creo Medical has announced that the FDA has cleared its HS1 haemostasis device, making it the second of Creo's devices to receive such clearance. We expect this significant milestone to be the first of a wave of regulatory clearances for Creo's pipeline of devices in both the US and EU. This news follows Creo's recent trading update in which the company discussed the impact of COVID-19 on its Clinical Education Programme and its current financials and cash position, which as of the end of Februa ....
23 Mar 2020
Cenkos: Creo Medical Group Plc -- Second FDA clearance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: Creo Medical Group Plc -- Second FDA clearance
Creo Medical Group Plc (CREO:LON) | 34.2 0 0.0% | Mkt Cap: 123.8m
- Published:
23 Mar 2020 -
Author:
Chris Donnellan -
Pages:
5
Creo Medical has announced that the FDA has cleared its HS1 haemostasis device, making it the second of Creo's devices to receive such clearance. We expect this significant milestone to be the first of a wave of regulatory clearances for Creo's pipeline of devices in both the US and EU. This news follows Creo's recent trading update in which the company discussed the impact of COVID-19 on its Clinical Education Programme and its current financials and cash position, which as of the end of Februa ....